26Apr 2021
Dapagliflozin Reduces Systolic Blood Pressure and Modulates Vasoactive Factors

Dapagliflozin Reduces Systolic Blood Pressure and Modulates Vasoactive Factors

Mechanisms underlying the improvements in blood pressure (BP) and congestive heart failure outcomes following treatment with dapagliflozin are not fully understood. We hypothesized that vasoactive mediators may be involved.

  • #endo-diabetology

Like

Save

Share